EP Patent

EP3406251A1 — Pyruvate kinase activators for use in therapy

Assigned to Agios Pharmaceuticals Inc · Expires 2018-11-28 · 7y expired

What this patent protects

Described herein are compounds that activate pyruvate kinase for use in methods of treatment.

USPTO Abstract

Described herein are compounds that activate pyruvate kinase for use in methods of treatment.

Drugs covered by this patent

Patent Metadata

Patent number
EP3406251A1
Jurisdiction
EP
Classification
—
Expires
2018-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Agios Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.